På tilbagetrækningstidspunktet var det derfor CHMP' s opfattelse, at de eventuelle fordele ved Diractin ikke opvejede de påviste risici.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that any benefits of Diractin did not outweigh the identified risks.